Paricalcitol for treatment of secondary hyperparathyroidism in CKD patients.
Drüeke
Tilman B
TB
Landais
Paul
P
D000085:Acetates / Q000494:pharmacology; D002117:Calcitriol / Q000494:pharmacology; D002118:Calcium / Q000097:blood; D017610:Calcium Compounds; D002908:Chronic Disease; D000069449:Cinacalcet; D017326:Clinical Trials, Phase III as Topic; D004872:Ergocalciferols / Q000627:therapeutic use*; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000097:blood / Q000188:drug therapy* / Q000209:etiology*; D007674:Kidney Diseases / Q000097:blood / Q000150:complications*; D009281:Naphthalenes / Q000494:pharmacology; D010281:Parathyroid Hormone / Q000097:blood; D010758:Phosphorus / Q000097:blood; D016032:Randomized Controlled Trials as Topic
D000085:Acetates; D017610:Calcium Compounds; D004872:Ergocalciferols; D009281:Naphthalenes; D010281:Parathyroid Hormone; D010758:Phosphorus; C084656:paricalcitol; D002117:Calcitriol; D002118:Calcium; D000069449:Cinacalcet; C120662:calcium acetate